dhodh in 1

DHODH-IN-1 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 25 nM. DHODH-IN-1 is an inhibitor of the pyrimidine biosynthetic pathway.

RORγt/DHODH-IN-1 (compound (R)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.083 μM) and DHODH (IC50: 0.172 μM), which exhibits significant in vivo anti-inflammatory effects.

RORγt/DHODH-IN-3 (compound (S)-14d) is a potent, orally active dual inhibitor of RORγt (IC50: 0.098 μM) and DHODH (IC50: 0.432 μM).RORγt/DHODH-IN-1 has significant in vivo anti-inflammatory effects.

RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor that can be used in the study of inflammatory bowel disease (IBD).

hDHODH-IN-12 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an inhibitory concentration (IC50) of 0.421 μM. As the rate-limiting enzyme in the de novo synthesis of pyrimidines, critical for DNA/RNA synthesis, DHODH is localized within the inner membrane of human mitochondria. hDHODH-IN-12 is applicable in lung cancer research [1].

CHIKV-IN-2, a chemical compound, exhibits potent inhibitory activity against the enzyme Dihydroorotate Dehydrogenase (DHODH), crucial for pyrimidine synthesis affecting various viruses' replication. It serves as an effective Chikungunya virus (CHIKV) inhibitor, demonstrating significant cellular antiviral activity (EC90=270 nM) and enhanced liver microsomal stability[1].

Farudodstat (ASLAN003) is an orally active and potent inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) with antitumor activity. It has the potential to be a first-in-class candidate in AML.